Physiology and molecular mechanism of glucocorticoid action;Fizjologia i molekularny mechanizm działania glikokortykoidów

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 64, Issue , 2010, Pages 133-145

  Nagalski, Andrzej ^a,b   Kiersztan, Anna ^a  

^a UNIVERSITY OF WARSAW   (Poland)

^b Laboratorium Neurodegeneracji   (Poland)

Author keywords

11 hydroxysteroids dehydrogenase; Addison's disease; Cushing's syndrome; Glucocorticoid receptor; Glucocorticoids; HPA axis

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR;

ADDISON DISEASE; CIRCADIAN RHYTHM; CUSHING SYNDROME; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

11-BETA-HYDROXYSTEROID DEHYDROGENASES; ADDISON DISEASE; CIRCADIAN RHYTHM; CUSHING SYNDROME; GLUCOCORTICOIDS; HUMANS; RECEPTORS, GLUCOCORTICOID;

EID: 77954744372     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Anagnostis P., Athyros V. G., Tziomalos K., Karagiannis A., Mikhailidis D. P.: Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J. Clin. Endocrinol. Metab., 2009;94:2692-2701
2. Atanasov A. G., Ignatova I. D., Nashev L. G., Dick B., Ferrari P., Frey F. J., Odermatt A.: Impaired protein stability of 11 β-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess. J. Am. Soc. Nephrol., 2007;18:1262-1270 (Pubitemid 46536912)
3. Barnes P. J.: Corticosteroid effects on cell signalling. Eur. Respir. J., 2006;27:413-426 (Pubitemid 43185854)
4. Bartel D. P.: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004;116:281-297
5. Bartholome B., Spies C. M., Gaber T., Schuchmann S., Berki T., Kunkel D., Bienert M., Radbruch A., Burmester G. R., Lauster R., Scheffold A., Buttgereit F.: Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and up-regulated after in vitro stimulation and in patients with rheumatoid arthritis. FASEB J., 2004;18:70-80 (Pubitemid 38076467)
6. Bornstein S. R., Engeland W. C., Ehrhart-Bornstein M., Herman J. P.: Dissociation of ACTH and glucocorticoids. Trends Endocrinol. Metab., 2008;19:175-180 (Pubitemid 351847836)
7. Buckingham J. C.: Glucocorticoids: exemplars of multi-tasking. Br. J. Pharmacol., 2006;147(Suppl. 1):S258-S268 (Pubitemid 43077284)
8. Buttgereit F., Straub R. H., Wehling M., Burmester G. R.: Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum., 2004;50:3408-3417 (Pubitemid 39488664)
9. Croxtall J. D., Choudhury Q., Flower R. J.: Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. Br. J. Pharmacol., 2000;130:289-298 (Pubitemid 30261038)
10. Datson N. A., Morsink M. C., Meijer O. C., de Kloet E. R.: Central corticosteroid actions: Search for gene targets. Eur. J. Pharmacol., 2008;583:272-289
11. Davies L., Karthikeyan N., Lynch J. T., Sial E. A., Gkourtsa A., Demonacos C., Krstic-Demonacos M.: Cross talk of signaling pathways in the regulation of the glucocorticoid receptor function. Mol. Endocrinol., 2008;22:1331-1344 (Pubitemid 351786994)
12. de Kloet E. R., Fitzsimons C. P., Datson N. A., Meijer O. C., Vreugdenhil E.: Glucocorticoid signaling and stress-related limbic susceptibility pathway: about receptors, transcription machinery and microRNA. Brain Res., 2009;1293:129-141
13. Dickmeis T.: Glucocorticoids and the circadian clock. J. Endocrinol., 2009;200:3-22
14. Dostert A., Heinzel T.: Negative glucocorticoid receptor response elements and their role in glucocorticoid action. Curr. Pharm. Des., 2004;10:2807-2816 (Pubitemid 39162399)
15. Draper N., Stewart P. M.: 11β-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J. Endocrinol., 2005;186:251-271 (Pubitemid 41167396)
16. Funder J. W.: Mineralocorticoid receptors: distribution and activation. Heart Fail. Rev., 2005;10:15-22 (Pubitemid 40895312)
17. Fuster D., Escher G., Vogt B., Ackermann D., Dick B., Frey B. M., Frey F. J.: Furosemide inhibits 11β-hydroxysteroid dehydrogenase type 2. Endocrinology, 1998;139:3849-3854 (Pubitemid 28512267)
18. Galliher-Beckley A. J., Cidlowski J. A.: Emerging roles of glucocorticoid receptor phosphorylation in modulating glucocorticoid hormone action in health and disease. IUBMB Life, 2009;61:979-986
19. Germain P., Staels B., Dacquet C., Spedding M., Laudet V.: Overview of nomenclature of nuclear receptors. Pharmacol. Rev., 2006;58:685-704 (Pubitemid 44833739)
20. Glass C. K.: Going nuclear in metabolic and cardiovascular disease. J. Clin. Invest., 2006;116:556-560 (Pubitemid 43326859)
21. Gomez-Sanchez E. P., Romero D. G., de Rodriguez A. F., Warden M. P., Krozowski Z., Gomez-Sanchez C. E.: Hexose-6-phosphate dehydrogenase and 11β-hydroxysteroid dehydrogenase-1 tissue distribution in the rat. Endocrinology, 2008;149:525-533 (Pubitemid 351159346)
22. Gong R., Morris D. J., Brem A. S.: Human renal 11β-hydroxysteroid dehydrogenase 1 functions and co-localizes with COX-2. Life Sci., 2008;82:631-637
23. Goulding N. J.: The molecular complexity of glucocorticoid actions in inflammation - a four-ring circus. Curr. Opin. Pharmacol., 2004;4:629-636 (Pubitemid 40267879)
24. Gross K. L., Cidlowski J. A.: Tissue-specific glucocorticoid action: a family affair. Trends Endocrinol. Metab., 2008;19:331-339
25. Gross K. L., Lu N. Z., Cidlowski J. A.: Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol. Cell. Endocrinol., 2009;300:7-16
26. Hale C., Wang M.: Development of 11β-HSD1 inhibitors for the treatment of type 2 diabetes. Mini Rev. Med. Chem., 2008;8:702-710
27. Han S. J., Lonard D. M., O'Malley B. W.: Multi-modulation of nuclear receptor coactivators through posttranslational modifications. Trends Endocrinol. Metab., 2009;20:8-15
28. Heitzer M. D., Wolf I. M., Sanchez E. R., Witchel S. F., DeFranco D. B.: Glucocorticoid receptor physiology. Rev. Endocr. Metab. Disord., 2007;8:321-330
29. Hewitt K. N., Walker E. A., Stewart P. M.: Minireview: hexose-6-phosphate dehydrogenase and redox control of 11β-hydroxysteroid dehydrogenase type 1 activity. Endocrinology, 2005;146:2539-2543 (Pubitemid 40695555)
30. Holmes M. C., Kotelevtsev Y., Mullins J. J., Seckl J. R.: Phenotypic analysis of mice bearing targeted deletions of 11β-hydroxysteroid dehydrogenases 1 and 2 genes. Mol. Cell. Endocrinol., 2001;171:15-20 (Pubitemid 32098193)
31. Lu N. Z., Cidlowski J. A.: Glucocorticoid receptor isoforms generate transcription specificity. Trends Cell. Biol., 2006;16:301-307 (Pubitemid 43884980)
32. Lu N. Z., Wardell S. E., Burnstein K. L., Defranco D., Fuller P. J., Giguere V., Hochberg R. B., McKay L., Renoir J. M., Weigel N. L., Wilson E. M., McDonnell D. P., Cidlowski J. A.: International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol. Rev., 2006;58:782-797 (Pubitemid 44833746)
33. Meijer O. C., Karssen A. M., de Kloet E. R.: Cell-and tissue-specific effects of corticosteroids in relation to glucocorticoid resistance: examples from the brain. J. Endocrinol., 2003;178:13-18 (Pubitemid 36927004)
34. Oppermann U.: Type 1 11β-hydroxysteroid dehydrogenase as universal drug target in metabolic diseases? Endocr. Metab. Immune Disord. Drug Targets, 2006;6:259-269 (Pubitemid 44383209)
35. Pariante C. M., Thomas S. A., Lovestone S., Makoff A., Kerwin R. W.: Do antidepressants regulate how cortisol affects the brain? Psychoneuroendocrinology, 2004;29:423-447 (Pubitemid 38121601)
36. Saltiel A. R.: New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell, 2001;104:517-529 (Pubitemid 32201947)
37. Sarabdjitsingh R. A., Meijer O. C., Schaaf M. J., de Kloet E. R.: Subregion-specific differences in translocation patterns of mineralocorticoid and glucocorticoid receptors in rat hippocampus. Brain Res., 2009;1249:43-53
38. Seckl J. R.: 11β-hydroxysteroid dehydrogenases: changing glucocorticoid action. Curr. Opin. Pharmacol., 2004;4:597-602 (Pubitemid 40267874)
39. Shibli-Rahhal A., Van Beek M., Schlechte J. A.: Cushing's syndrome. Clin. Dermatol., 2006;24:260-265 (Pubitemid 43975261)
40. So A. Y., Chaivorapol C., Bolton E. C., Li H., Yamamoto K. R.: Determinants of cell-and gene-specific transcriptional regulation by the glucocorticoid receptor. PLoS Genet., 2007;3:e94
41. Stahn C., Buttgereit F.: Genomic and nongenomic effects of glucocorticoids. Nat. Clin. Pract. Rheumatol., 2008;4:525-533
42. Stahn C., Löwenberg M., Hommes D. W., Buttgereit F.: Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol. Cell. Endocrinol., 2007;275:71-78 (Pubitemid 47259281)
43. Szeto A., Gonzales J. A., Spitzer S. B., Levine J. E., Zaias J., Saab P. G., Schneiderman N., McCabe P. M.: Circulating levels of glucocorticoid hormones in WHHL and NZW rabbits: circadian cycle and response to repeated social encounter. Psychoneuroendocrinology, 2004;29:861-866 (Pubitemid 38716111)
44. Tasker J. G., Di S., Malcher-Lopes R.: Minireview: rapid glucocorticoid signaling via membrane-associated receptors. Endocrinology, 2006;147:5549-5556 (Pubitemid 44833470)
45. Ten S., New M., Maclaren N.: Clinical review 130: Addison's disease 2001. J. Clin. Endocrinol. Metab., 2001;86:2909-2922 (Pubitemid 32673441)
46. Tisdale M. J.: Cachexia in cancer patients. Nat. Rev. Cancer, 2002;2:862-871 (Pubitemid 37328904)
47. Torpy D. J., Ho J. T.: Corticosteroid-binding globulin gene polymorphisms: clinical implications and links to idiopathic chronic fatigue disorders. Clin. Endocrinol., 2007;67:161-167 (Pubitemid 47076314)
48. van der Laan S., Meijer O. C.: Pharmacology of glucocorticoids: beyond receptors. Eur. J. Pharmacol., 2008;585:483-491
49. van Raalte D. H., Ouwens D. M., Diamant M.: Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur. J. Clin. Invest., 2009;39:81-93
50. Vegiopoulos A., Herzig S.: Glucocorticoids, metabolism and metabolic diseases. Mol. Cell. Endocrinol., 2007;275:43-61 (Pubitemid 47259280)
51. Walker B. R.: Cortisol - cause and cure for metabolic syndrome? Diabet. Med., 2006;23:1281-1288 (Pubitemid 44787789)
52. Walker E. A., Ahmed A., Lavery G. G., Tomlinson J. W., Kim S. Y., Cooper M. S., Ride J. P., Hughes B. A., Shackleton C. H., McKiernan P., Elias E., Chou J. Y., Stewart P. M.: 11β-hydroxysteroid dehydrogenase type 1 regulation by intracellular glucose 6-phosphate provides evidence for a novel link between glucose metabolism and hypothalamo-pituitary-adrenal axis function. J. Biol. Chem., 2007;282:27030-27036 (Pubitemid 47501934)
53. Wamil M., Seckl J. R.: Inhibition of 11β-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Discov. Today, 2007;12:504-520 (Pubitemid 47031664)